298 related articles for article (PubMed ID: 24168191)
1. Roles of epithelial-mesenchymal transition in cancer drug resistance.
Shang Y; Cai X; Fan D
Curr Cancer Drug Targets; 2013 Nov; 13(9):915-29. PubMed ID: 24168191
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-to-Mesenchymal Transition: Liaison between Cancer Metastasis and Drug Resistance.
Du F; Liu H; Lu Y; Zhao X; Fan D
Crit Rev Oncog; 2017; 22(3-4):275-282. PubMed ID: 29604904
[TBL] [Abstract][Full Text] [Related]
3. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies.
Sui H; Zhu L; Deng W; Li Q
Oncol Res Treat; 2014; 37(10):584-9. PubMed ID: 25342509
[TBL] [Abstract][Full Text] [Related]
5. SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell.
Liu H; Gu Y; Yin J; Zheng G; Wang C; Zhang Z; Deng M; Liu J; Jia X; He Z
Cell Signal; 2014 Dec; 26(12):2710-20. PubMed ID: 25152373
[TBL] [Abstract][Full Text] [Related]
6. Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition.
Sha J; Bai Y; Ngo HX; Okui T; Kanno T
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208465
[TBL] [Abstract][Full Text] [Related]
7. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?
van Staalduinen J; Baker D; Ten Dijke P; van Dam H
Oncogene; 2018 Nov; 37(48):6195-6211. PubMed ID: 30002444
[TBL] [Abstract][Full Text] [Related]
9. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer.
Li P; Yang R; Gao WQ
Mol Cancer; 2014 Mar; 13():55. PubMed ID: 24618337
[TBL] [Abstract][Full Text] [Related]
10. Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance.
Ashrafizadeh M; Zarrabi A; Hushmandi K; Kalantari M; Mohammadinejad R; Javaheri T; Sethi G
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32503307
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT).
Cho ES; Kang HE; Kim NH; Yook JI
Arch Pharm Res; 2019 Jan; 42(1):14-24. PubMed ID: 30649699
[TBL] [Abstract][Full Text] [Related]
12. The relationship between platinum drug resistance and epithelial-mesenchymal transition.
Brozovic A
Arch Toxicol; 2017 Feb; 91(2):605-619. PubMed ID: 28032148
[TBL] [Abstract][Full Text] [Related]
13. The role of epithelial-mesenchymal transition-regulating transcription factors in anti-cancer drug resistance.
Seo J; Ha J; Kang E; Cho S
Arch Pharm Res; 2021 Mar; 44(3):281-292. PubMed ID: 33768509
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-mesenchymal transition and drug resistance in breast cancer (Review).
Huang J; Li H; Ren G
Int J Oncol; 2015 Sep; 47(3):840-8. PubMed ID: 26202679
[TBL] [Abstract][Full Text] [Related]
15. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
16. Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer.
Garg M
Expert Opin Ther Targets; 2015 Feb; 19(2):285-97. PubMed ID: 25563894
[TBL] [Abstract][Full Text] [Related]
17. EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.
Tulchinsky E; Demidov O; Kriajevska M; Barlev NA; Imyanitov E
Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):29-39. PubMed ID: 30419315
[TBL] [Abstract][Full Text] [Related]
18. Regulation of EMT by Notch signaling pathway in tumor progression.
Li Y; Ma J; Qian X; Wu Q; Xia J; Miele L; Sarkar FH; Wang Z
Curr Cancer Drug Targets; 2013 Nov; 13(9):957-62. PubMed ID: 24168187
[TBL] [Abstract][Full Text] [Related]
19. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer.
Huang RY; Chung VY; Thiery JP
Curr Drug Targets; 2012 Dec; 13(13):1649-53. PubMed ID: 23061545
[TBL] [Abstract][Full Text] [Related]
20. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Brown WS; Akhand SS; Wendt MK
Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]